DE102007026550A1 - Extrudate mit verbesserter Geschmacksmaskierung - Google Patents
Extrudate mit verbesserter Geschmacksmaskierung Download PDFInfo
- Publication number
- DE102007026550A1 DE102007026550A1 DE102007026550A DE102007026550A DE102007026550A1 DE 102007026550 A1 DE102007026550 A1 DE 102007026550A1 DE 102007026550 A DE102007026550 A DE 102007026550A DE 102007026550 A DE102007026550 A DE 102007026550A DE 102007026550 A1 DE102007026550 A1 DE 102007026550A1
- Authority
- DE
- Germany
- Prior art keywords
- extrudates
- release
- pharmaceutics
- taste
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000019640 taste Nutrition 0.000 title description 13
- 230000000873 masking effect Effects 0.000 title description 6
- 239000003814 drug Substances 0.000 claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 239000013543 active substance Substances 0.000 claims abstract description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 claims description 13
- 150000002632 lipids Chemical class 0.000 claims description 12
- -1 glycerol ester Chemical class 0.000 claims description 11
- 239000000654 additive Substances 0.000 claims description 7
- 238000002844 melting Methods 0.000 claims description 7
- 230000008018 melting Effects 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- GNWCZBXSKIIURR-UHFFFAOYSA-N (2-docosanoyloxy-3-hydroxypropyl) docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCCCCCC GNWCZBXSKIIURR-UHFFFAOYSA-N 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 description 22
- 239000000203 mixture Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 239000001257 hydrogen Substances 0.000 description 15
- 229910052739 hydrogen Inorganic materials 0.000 description 15
- 238000001125 extrusion Methods 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000003925 fat Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 150000004677 hydrates Chemical class 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 239000001993 wax Substances 0.000 description 7
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000003475 lamination Methods 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229960000740 enrofloxacin Drugs 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 229940124307 fluoroquinolone Drugs 0.000 description 5
- 150000002431 hydrogen Chemical group 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000008119 colloidal silica Substances 0.000 description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- LZLXHGFNOWILIY-APPDUMDISA-N pradofloxacin Chemical compound C12=C(C#N)C(N3C[C@H]4NCCC[C@H]4C3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 LZLXHGFNOWILIY-APPDUMDISA-N 0.000 description 4
- 239000007962 solid dispersion Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920003148 Eudragit® E polymer Polymers 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920001800 Shellac Polymers 0.000 description 3
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940116364 hard fat Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 229920000058 polyacrylate Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229960001248 pradofloxacin Drugs 0.000 description 3
- 229960002957 praziquantel Drugs 0.000 description 3
- 150000007660 quinolones Chemical class 0.000 description 3
- 239000004208 shellac Substances 0.000 description 3
- 229940113147 shellac Drugs 0.000 description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 3
- 235000013874 shellac Nutrition 0.000 description 3
- 238000012031 short term test Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- BPFYOAJNDMUVBL-UHFFFAOYSA-N LSM-5799 Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3N(C)COC1=C32 BPFYOAJNDMUVBL-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- QIPQASLPWJVQMH-DTORHVGOSA-N Orbifloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(F)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F QIPQASLPWJVQMH-DTORHVGOSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000000507 anthelmentic effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 238000005422 blasting Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- NOCJXYPHIIZEHN-UHFFFAOYSA-N difloxacin Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1 NOCJXYPHIIZEHN-UHFFFAOYSA-N 0.000 description 2
- 229950001733 difloxacin Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 108010056417 emodepside Proteins 0.000 description 2
- ZMQMTKVVAMWKNY-YSXLEBCMSA-N emodepside Chemical compound C([C@@H]1C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@H](C(O[C@H](CC=2C=CC(=CC=2)N2CCOCC2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O1)=O)CC(C)C)C(C=C1)=CC=C1N1CCOCC1 ZMQMTKVVAMWKNY-YSXLEBCMSA-N 0.000 description 2
- 229960001575 emodepside Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- 150000002314 glycerols Chemical class 0.000 description 2
- 229940049654 glyceryl behenate Drugs 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- DXKRGNXUIRKXNR-UHFFFAOYSA-N ibafloxacin Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=C(C)C(F)=C3 DXKRGNXUIRKXNR-UHFFFAOYSA-N 0.000 description 2
- 229950007954 ibafloxacin Drugs 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960002531 marbofloxacin Drugs 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229960004780 orbifloxacin Drugs 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 150000005691 triesters Chemical class 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BUHVIAUBTBOHAG-FOYDDCNASA-N (2r,3r,4s,5r)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC(OC)=CC(C(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=2C(=CC=CC=2)C)=C1 BUHVIAUBTBOHAG-FOYDDCNASA-N 0.000 description 1
- QKDHBVNJCZBTMR-LLVKDONJSA-N (R)-temafloxacin Chemical compound C1CN[C@H](C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-LLVKDONJSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Polymers FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OCINXEZVIIVXFU-UHFFFAOYSA-N 1-methyl-3-[3-methyl-4-[4-(trifluoromethylthio)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(SC(F)(F)F)C=C1 OCINXEZVIIVXFU-UHFFFAOYSA-N 0.000 description 1
- ZFRUGZMCGCYBRC-UHFFFAOYSA-N 1h-1,8-naphthyridin-2-one Chemical compound C1=CC=NC2=NC(O)=CC=C21 ZFRUGZMCGCYBRC-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- ZSZFUDFOPOMEET-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1C(C#N)C1=C(Cl)C=C(N2C(NC(=O)C=N2)=O)C=C1Cl ZSZFUDFOPOMEET-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- XBHBWNFJWIASRO-UHFFFAOYSA-N 6-fluoro-1-(4-fluorophenyl)-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1=CC=C(F)C=C1 XBHBWNFJWIASRO-UHFFFAOYSA-N 0.000 description 1
- UBGCCYGMLOBJOJ-UHFFFAOYSA-N 7-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN2CCC1CC2 UBGCCYGMLOBJOJ-UHFFFAOYSA-N 0.000 description 1
- WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N Behenic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000030939 Bubalus bubalis Species 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 241000283014 Dama Species 0.000 description 1
- QMLVECGLEOSESV-RYUDHWBXSA-N Danofloxacin Chemical compound C([C@@H]1C[C@H]2CN1C)N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 QMLVECGLEOSESV-RYUDHWBXSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000939135 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 27 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000282330 Procyon lotor Species 0.000 description 1
- 241000283011 Rangifer Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102100029736 Ubiquitin carboxyl-terminal hydrolase 27 Human genes 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229950011614 binfloxacin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- SMBKCSPGKDEPFO-UHFFFAOYSA-L calcium;docosanoate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCCCCCC([O-])=O SMBKCSPGKDEPFO-UHFFFAOYSA-L 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 229960004621 cinoxacin Drugs 0.000 description 1
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000000641 cold extrusion Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229960004385 danofloxacin Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960000248 diclazuril Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002706 dry binder Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- LGUDKOQUWIHXOV-UHFFFAOYSA-N epsiprantel Chemical compound C1C(C2=CC=CC=C2CCC2)N2C(=O)CN1C(=O)C1CCCCC1 LGUDKOQUWIHXOV-UHFFFAOYSA-N 0.000 description 1
- 229960005362 epsiprantel Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 1
- 229960003306 fleroxacin Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000002271 gyrase inhibitor Substances 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 239000004611 light stabiliser Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
- 229960004236 pefloxacin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 229960003508 ponazuril Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 239000003306 quinoline derived antiinfective agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229950007734 sarafloxacin Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960004576 temafloxacin Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960000898 toltrazuril Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229950008187 tosufloxacin Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- JATLJHBAMQKRDH-UHFFFAOYSA-N vebufloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCN(C)CC1 JATLJHBAMQKRDH-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Seasonings (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- General Preparation And Processing Of Foods (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Fats And Perfumes (AREA)
Priority Applications (39)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007026550A DE102007026550A1 (de) | 2007-06-08 | 2007-06-08 | Extrudate mit verbesserter Geschmacksmaskierung |
| DK08758803.4T DK2170272T3 (en) | 2007-06-08 | 2008-05-28 | EXTRADATES WITH IMPROVED TASTE MASKING |
| HUE08758803A HUE032719T2 (en) | 2007-06-08 | 2008-05-28 | Extruded product with improved taste masking ability |
| AU2008258887A AU2008258887B2 (en) | 2007-06-08 | 2008-05-28 | Improved taste-masking extrudates |
| JP2010510673A JP5775302B2 (ja) | 2007-06-08 | 2008-05-28 | 味のマスキングが改善された押出物 |
| MYPI20095156A MY157780A (en) | 2007-06-08 | 2008-05-28 | Extrudates with improved taste masking |
| NZ581670A NZ581670A (en) | 2007-06-08 | 2008-05-28 | Improved taste-masking extrudates |
| MX2009011999A MX2009011999A (es) | 2007-06-08 | 2008-05-28 | Extruidos con enmascaramiento del sabor mejorado. |
| RU2009148576/15A RU2009148576A (ru) | 2007-06-08 | 2008-05-28 | Экструдаты с улучшенной маскировкой вкуса |
| KR1020157025300A KR20150110825A (ko) | 2007-06-08 | 2008-05-28 | 개선된 맛-차폐 압출물 |
| UAA200913975A UA97401C2 (ru) | 2007-06-08 | 2008-05-28 | Экструдат с улучшенной маскировкой вкуса |
| PL08758803T PL2170272T3 (pl) | 2007-06-08 | 2008-05-28 | Wyroby wytłaczane o poprawionym maskowaniu smaku |
| KR1020097024644A KR101600800B1 (ko) | 2007-06-08 | 2008-05-28 | 개선된 맛-차폐 압출물 |
| US12/602,002 US20100197571A1 (en) | 2007-06-08 | 2008-05-28 | Extrudates with improved taste masking |
| SI200831803A SI2170272T1 (sl) | 2007-06-08 | 2008-05-28 | Izboljšani ekstrudat za maskiranje okusa |
| EP08758803.4A EP2170272B1 (de) | 2007-06-08 | 2008-05-28 | Extrudate mit verbesserter geschmacksmaskierung |
| PCT/EP2008/004218 WO2008148484A1 (de) | 2007-06-08 | 2008-05-28 | Extrudate mit verbesserter geschmacksmaskierung |
| ES08758803.4T ES2625138T3 (es) | 2007-06-08 | 2008-05-28 | Extrudidos con enmascaramiento del sabor mejorado |
| BRPI0812432A BRPI0812432B8 (pt) | 2007-06-08 | 2008-05-28 | extrusados, seu uso, e medicamento |
| PT87588034T PT2170272T (pt) | 2007-06-08 | 2008-05-28 | Extrudados com mascaramento de sabor melhorado |
| CN200880019366A CN101677946A (zh) | 2007-06-08 | 2008-05-28 | 具有改善的掩味的挤出物 |
| CA2689486A CA2689486C (en) | 2007-06-08 | 2008-05-28 | Extrudates with improved taste masking |
| CL2008001575A CL2008001575A1 (es) | 2007-06-08 | 2008-05-30 | Composicion farmaceutica extruida que presenta un diametro de hebra de 0,5 mm o inferior, que contiene un soporte lipidico como coadyuvante, util para encubrir el sabor. |
| UY31117A UY31117A1 (es) | 2007-06-08 | 2008-06-02 | Productos extruidos con enmascaramiento del sabor mejorado |
| PE2008000928A PE20090761A1 (es) | 2007-06-08 | 2008-06-02 | Productos extruidos con enmascaramiento del sabor mejorado |
| ARP080102433A AR066914A1 (es) | 2007-06-08 | 2008-06-06 | Productos extruidos con enmascaramiento del sabor mejorado |
| TW097121022A TWI483738B (zh) | 2007-06-08 | 2008-06-06 | 具有改良之味道遮蔽性的擠出物 |
| IL201708A IL201708A0 (en) | 2007-06-08 | 2009-10-22 | Improved taste-masking extrudates |
| GT200900287A GT200900287A (es) | 2007-06-08 | 2009-11-04 | Extrudidos con enmascaramiento del sabor mejorado |
| CO09124495A CO6260054A2 (es) | 2007-06-08 | 2009-11-04 | Extruidos con enmascaramiento del sabor mejorado |
| CR11096A CR11096A (es) | 2007-06-08 | 2009-11-05 | Extrudidos con enmascaramiento del sabor mejorado |
| NI200900198A NI200900198A (es) | 2007-06-08 | 2009-11-05 | Extrudidos con mascaramiento del sabor mejorado. |
| SV2009003403A SV2009003403A (es) | 2007-06-08 | 2009-11-05 | Extrudidos con enmascaramiento del sabor mejorado |
| DO2009000255A DOP2009000255A (es) | 2007-06-08 | 2009-11-05 | Extrudidos con enmascaramiento del sabor mejorado |
| EC2009009716A ECSP099716A (es) | 2007-06-08 | 2009-11-06 | Extrudidos con enmascaramiento del sabor mejorado |
| ZA2009/08647A ZA200908647B (en) | 2007-06-08 | 2009-12-07 | Improved taste-masking extrudates |
| JP2014017794A JP2014114310A (ja) | 2007-06-08 | 2014-01-31 | 味のマスキングが改善された押出物 |
| RU2014124814/15A RU2014124814A (ru) | 2007-06-08 | 2014-06-18 | Экструдаты с улучшенной маскировкой вкуса |
| HRP20170747TT HRP20170747T1 (hr) | 2007-06-08 | 2017-05-18 | Poboljšani ekstrudati za maskiranje okusa |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007026550A DE102007026550A1 (de) | 2007-06-08 | 2007-06-08 | Extrudate mit verbesserter Geschmacksmaskierung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE102007026550A1 true DE102007026550A1 (de) | 2008-12-11 |
Family
ID=39790368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102007026550A Withdrawn DE102007026550A1 (de) | 2007-06-08 | 2007-06-08 | Extrudate mit verbesserter Geschmacksmaskierung |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US20100197571A1 (ru) |
| EP (1) | EP2170272B1 (ru) |
| JP (2) | JP5775302B2 (ru) |
| KR (2) | KR20150110825A (ru) |
| CN (1) | CN101677946A (ru) |
| AR (1) | AR066914A1 (ru) |
| AU (1) | AU2008258887B2 (ru) |
| BR (1) | BRPI0812432B8 (ru) |
| CA (1) | CA2689486C (ru) |
| CL (1) | CL2008001575A1 (ru) |
| CO (1) | CO6260054A2 (ru) |
| CR (1) | CR11096A (ru) |
| DE (1) | DE102007026550A1 (ru) |
| DK (1) | DK2170272T3 (ru) |
| DO (1) | DOP2009000255A (ru) |
| EC (1) | ECSP099716A (ru) |
| ES (1) | ES2625138T3 (ru) |
| GT (1) | GT200900287A (ru) |
| HR (1) | HRP20170747T1 (ru) |
| HU (1) | HUE032719T2 (ru) |
| IL (1) | IL201708A0 (ru) |
| MX (1) | MX2009011999A (ru) |
| MY (1) | MY157780A (ru) |
| NI (1) | NI200900198A (ru) |
| NZ (1) | NZ581670A (ru) |
| PE (1) | PE20090761A1 (ru) |
| PL (1) | PL2170272T3 (ru) |
| PT (1) | PT2170272T (ru) |
| RU (2) | RU2009148576A (ru) |
| SI (1) | SI2170272T1 (ru) |
| SV (1) | SV2009003403A (ru) |
| TW (1) | TWI483738B (ru) |
| UA (1) | UA97401C2 (ru) |
| UY (1) | UY31117A1 (ru) |
| WO (1) | WO2008148484A1 (ru) |
| ZA (1) | ZA200908647B (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2172191A1 (en) * | 2008-10-01 | 2010-04-07 | Heinrich-Heine-Universität Düsseldorf | Lipid pellets with enhanced taste-masking |
| CN102238940B (zh) * | 2008-12-05 | 2014-07-30 | 拜耳知识产权有限责任公司 | 含针状活性物质的挤出物 |
| DE102009012423A1 (de) * | 2009-03-10 | 2010-09-16 | Bayer Animal Health Gmbh | Zubereitung auf Ölbasis |
| HU231017B1 (hu) | 2012-05-08 | 2019-11-28 | LAVET Gyógyszeripari Kft. | Praziquantel tartalmú ízfedett formulációk |
| CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
| EP3181317A1 (de) * | 2015-12-18 | 2017-06-21 | LANXESS Deutschland GmbH | Verfahren zur herstellung von feststoffpartikeln |
| CN108888598A (zh) * | 2018-08-01 | 2018-11-27 | 江西成必信生物科技有限公司 | 口服易吸收的布他磷及其制备方法 |
| CN111529499B (zh) * | 2020-06-11 | 2021-09-17 | 华中农业大学 | 一种兽用恩诺沙星风味片剂及其制备方法 |
| EP4208157A1 (en) | 2020-09-04 | 2023-07-12 | Elanco Us Inc. | Palatable formulations |
Citations (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4382892A (en) | 1980-09-02 | 1983-05-10 | Daiichi Seiyaku Co., Ltd. | Benzoxazine derivatives |
| US4472405A (en) | 1982-11-12 | 1984-09-18 | Riker Laboratories, Inc. | Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives |
| US4670444A (en) | 1980-09-03 | 1987-06-02 | Bayer Aktiengesellschaft | 7-amino-1-cyclopropyl-4-oxo-1, 4-dihydro-quinoline-and naphthyridine-3-carboxylic acids and antibacterial agents containing these compounds |
| US4704459A (en) | 1985-01-23 | 1987-11-03 | Toyama Chemical Co., Ltd. | Process for producing 1-substituted aryl-1,4-dihydro-4-oxonaphthyridine derivatives, and processes for producing the intermediates |
| US4730000A (en) | 1984-04-09 | 1988-03-08 | Abbott Laboratories | Quinoline antibacterial compounds |
| US4861779A (en) | 1985-09-18 | 1989-08-29 | Pfizer Inc. | Anti-bacterial substituted bridged-diazabicycloalkyl quinolone carboxylic acids |
| WO1997031001A1 (de) | 1996-02-23 | 1997-08-28 | Bayer Aktiengesellschaft | Gegebenenfalls substituierte 8-cyan-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäuren und ihre derivate |
| WO1998003157A1 (de) | 1996-07-17 | 1998-01-29 | Bayer Aktiengesellschaft | Oral applizierbare granulate von hexahydropyrazinderivaten |
| FR2753904A1 (fr) | 1996-10-01 | 1998-04-03 | Gattefosse Ets Sa | Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication |
| EP0855183A2 (de) | 1997-01-24 | 1998-07-29 | Hoechst Aktiengesellschaft | Herstellung geschmackskaschierter Zubereitungen antibakteriell wirksamer Chinolonderivaten |
| WO2000031076A1 (de) | 1998-11-25 | 2000-06-02 | Bayer Aktiengesellschaft | Kristallmodifikation b von 8-cyan- 1-cyclopropyl -7-(1s,6s-2, 8-diazabicyclo -[4.3.0]nonan -8-yl)-6- fluor-1, 4-dihydro- 4-oxo-3- chinolincarbonsaure |
| US6171615B1 (en) | 1998-07-06 | 2001-01-09 | Gattefoss{acute over (e)} | Sustained release theophylline formulations, excipient systems and methods of production |
| WO2002058669A1 (en) | 2001-01-24 | 2002-08-01 | Bayer Healthcare Llc | Solid phase dispersion of quinolone- or naphthyridonecarboxylic acids |
| WO2003030653A2 (en) | 2001-10-05 | 2003-04-17 | Rubicon Scientific Llc | Animal feeds including actives and methods of using same |
| WO2003072083A2 (de) | 2002-02-27 | 2003-09-04 | Röhm GmbH & Co. KG | Schmelzextrusion von wirkstoffsalzen |
| WO2004014346A1 (en) | 2002-08-06 | 2004-02-19 | Pfizer Products Inc. | Palatable controlled-release formulation for companion animals |
| WO2004066976A1 (de) | 2003-01-28 | 2004-08-12 | Röhm GmbH & Co. KG | Verfahren zur herstellung einer oralen arzneiform mit unmittelbarem zerfall und wirkstofffreisetzung |
| WO2005097064A2 (en) | 2004-04-12 | 2005-10-20 | Pfizer Products Inc. | Taste-masked drugs in rupturing multiparticulates |
| WO2005097789A1 (de) | 2004-04-01 | 2005-10-20 | Bayer Healthcare Ag | Neue kristalline form von 8-cyan-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61240963A (ja) * | 1985-04-18 | 1986-10-27 | ユニチカ株式会社 | 創傷被覆保護材 |
| JP2579610B2 (ja) * | 1990-09-28 | 1997-02-05 | 鳥取大学長 | 生体内充填剤 |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| AUPM969994A0 (en) * | 1994-11-28 | 1994-12-22 | Virbac S.A. | Equine anthelmintic formulations |
| JP3418274B2 (ja) * | 1995-06-05 | 2003-06-16 | 日本化薬株式会社 | 口腔内感触の良好な錠剤 |
| CA2260143C (en) * | 1996-07-30 | 2004-07-13 | Ashmont Holdings Limited | Anthelmintic formulations |
| BR9912533A (pt) * | 1998-07-31 | 2002-02-13 | Otsuka Pharma Co Ltd | Composição farmacêutica tendo sabor melhorado |
| US6500463B1 (en) * | 1999-10-01 | 2002-12-31 | General Mills, Inc. | Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
| MXPA02012795A (es) * | 2000-06-28 | 2004-07-30 | Teva Pharma | Carvedilol. |
| US6716448B2 (en) * | 2001-10-05 | 2004-04-06 | Rubicon Scientific Llc | Domesticated household pet food including maintenance amounts of ivermectin |
| JP2004099442A (ja) * | 2002-09-04 | 2004-04-02 | Nisshin Pharma Inc | 難溶性薬物含有製剤およびその製造方法 |
| US20040062778A1 (en) * | 2002-09-26 | 2004-04-01 | Adi Shefer | Surface dissolution and/or bulk erosion controlled release compositions and devices |
| KR20050075408A (ko) * | 2002-12-13 | 2005-07-20 | 시락 아게 | 트라마돌 및 토피라메이트를 포함하는 방출 조절형 제제 |
| MY135852A (en) * | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
| US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| US20050163842A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Rosiglitazone and metformin formulations |
| JP4210615B2 (ja) * | 2004-03-26 | 2009-01-21 | エスエス製薬株式会社 | 不快な味がマスキングされた製剤 |
| GB2418854B (en) * | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
| JP4731941B2 (ja) * | 2005-02-14 | 2011-07-27 | 大正薬品工業株式会社 | 経口製剤用粒子 |
| US8900637B2 (en) * | 2005-12-02 | 2014-12-02 | Lupin Limited | Stable taste masked formulations of cephalosporins |
-
2007
- 2007-06-08 DE DE102007026550A patent/DE102007026550A1/de not_active Withdrawn
-
2008
- 2008-05-28 EP EP08758803.4A patent/EP2170272B1/de active Active
- 2008-05-28 KR KR1020157025300A patent/KR20150110825A/ko not_active Application Discontinuation
- 2008-05-28 KR KR1020097024644A patent/KR101600800B1/ko not_active IP Right Cessation
- 2008-05-28 ES ES08758803.4T patent/ES2625138T3/es active Active
- 2008-05-28 US US12/602,002 patent/US20100197571A1/en not_active Abandoned
- 2008-05-28 RU RU2009148576/15A patent/RU2009148576A/ru unknown
- 2008-05-28 HU HUE08758803A patent/HUE032719T2/en unknown
- 2008-05-28 CA CA2689486A patent/CA2689486C/en not_active Expired - Fee Related
- 2008-05-28 PL PL08758803T patent/PL2170272T3/pl unknown
- 2008-05-28 UA UAA200913975A patent/UA97401C2/ru unknown
- 2008-05-28 DK DK08758803.4T patent/DK2170272T3/en active
- 2008-05-28 PT PT87588034T patent/PT2170272T/pt unknown
- 2008-05-28 MY MYPI20095156A patent/MY157780A/en unknown
- 2008-05-28 NZ NZ581670A patent/NZ581670A/en not_active IP Right Cessation
- 2008-05-28 CN CN200880019366A patent/CN101677946A/zh active Pending
- 2008-05-28 WO PCT/EP2008/004218 patent/WO2008148484A1/de active Application Filing
- 2008-05-28 BR BRPI0812432A patent/BRPI0812432B8/pt active IP Right Grant
- 2008-05-28 JP JP2010510673A patent/JP5775302B2/ja not_active Expired - Fee Related
- 2008-05-28 AU AU2008258887A patent/AU2008258887B2/en active Active
- 2008-05-28 SI SI200831803A patent/SI2170272T1/sl unknown
- 2008-05-28 MX MX2009011999A patent/MX2009011999A/es active IP Right Grant
- 2008-05-30 CL CL2008001575A patent/CL2008001575A1/es unknown
- 2008-06-02 UY UY31117A patent/UY31117A1/es not_active Application Discontinuation
- 2008-06-02 PE PE2008000928A patent/PE20090761A1/es not_active Application Discontinuation
- 2008-06-06 TW TW097121022A patent/TWI483738B/zh not_active IP Right Cessation
- 2008-06-06 AR ARP080102433A patent/AR066914A1/es unknown
-
2009
- 2009-10-22 IL IL201708A patent/IL201708A0/en unknown
- 2009-11-04 GT GT200900287A patent/GT200900287A/es unknown
- 2009-11-04 CO CO09124495A patent/CO6260054A2/es not_active Application Discontinuation
- 2009-11-05 CR CR11096A patent/CR11096A/es unknown
- 2009-11-05 SV SV2009003403A patent/SV2009003403A/es not_active Application Discontinuation
- 2009-11-05 NI NI200900198A patent/NI200900198A/es unknown
- 2009-11-05 DO DO2009000255A patent/DOP2009000255A/es unknown
- 2009-11-06 EC EC2009009716A patent/ECSP099716A/es unknown
- 2009-12-07 ZA ZA2009/08647A patent/ZA200908647B/en unknown
-
2014
- 2014-01-31 JP JP2014017794A patent/JP2014114310A/ja active Pending
- 2014-06-18 RU RU2014124814/15A patent/RU2014124814A/ru not_active Application Discontinuation
-
2017
- 2017-05-18 HR HRP20170747TT patent/HRP20170747T1/hr unknown
Patent Citations (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4382892A (en) | 1980-09-02 | 1983-05-10 | Daiichi Seiyaku Co., Ltd. | Benzoxazine derivatives |
| US4670444B1 (en) | 1980-09-03 | 1999-02-09 | Bayer Ag | and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds |
| US4670444A (en) | 1980-09-03 | 1987-06-02 | Bayer Aktiengesellschaft | 7-amino-1-cyclopropyl-4-oxo-1, 4-dihydro-quinoline-and naphthyridine-3-carboxylic acids and antibacterial agents containing these compounds |
| US4472405A (en) | 1982-11-12 | 1984-09-18 | Riker Laboratories, Inc. | Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives |
| US4730000A (en) | 1984-04-09 | 1988-03-08 | Abbott Laboratories | Quinoline antibacterial compounds |
| US4704459A (en) | 1985-01-23 | 1987-11-03 | Toyama Chemical Co., Ltd. | Process for producing 1-substituted aryl-1,4-dihydro-4-oxonaphthyridine derivatives, and processes for producing the intermediates |
| US4861779A (en) | 1985-09-18 | 1989-08-29 | Pfizer Inc. | Anti-bacterial substituted bridged-diazabicycloalkyl quinolone carboxylic acids |
| WO1997031001A1 (de) | 1996-02-23 | 1997-08-28 | Bayer Aktiengesellschaft | Gegebenenfalls substituierte 8-cyan-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäuren und ihre derivate |
| WO1998003157A1 (de) | 1996-07-17 | 1998-01-29 | Bayer Aktiengesellschaft | Oral applizierbare granulate von hexahydropyrazinderivaten |
| FR2753904A1 (fr) | 1996-10-01 | 1998-04-03 | Gattefosse Ets Sa | Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication |
| EP0855183A2 (de) | 1997-01-24 | 1998-07-29 | Hoechst Aktiengesellschaft | Herstellung geschmackskaschierter Zubereitungen antibakteriell wirksamer Chinolonderivaten |
| US6171615B1 (en) | 1998-07-06 | 2001-01-09 | Gattefoss{acute over (e)} | Sustained release theophylline formulations, excipient systems and methods of production |
| WO2000031076A1 (de) | 1998-11-25 | 2000-06-02 | Bayer Aktiengesellschaft | Kristallmodifikation b von 8-cyan- 1-cyclopropyl -7-(1s,6s-2, 8-diazabicyclo -[4.3.0]nonan -8-yl)-6- fluor-1, 4-dihydro- 4-oxo-3- chinolincarbonsaure |
| WO2002058669A1 (en) | 2001-01-24 | 2002-08-01 | Bayer Healthcare Llc | Solid phase dispersion of quinolone- or naphthyridonecarboxylic acids |
| WO2003030653A2 (en) | 2001-10-05 | 2003-04-17 | Rubicon Scientific Llc | Animal feeds including actives and methods of using same |
| WO2003072083A2 (de) | 2002-02-27 | 2003-09-04 | Röhm GmbH & Co. KG | Schmelzextrusion von wirkstoffsalzen |
| WO2004014346A1 (en) | 2002-08-06 | 2004-02-19 | Pfizer Products Inc. | Palatable controlled-release formulation for companion animals |
| WO2004066976A1 (de) | 2003-01-28 | 2004-08-12 | Röhm GmbH & Co. KG | Verfahren zur herstellung einer oralen arzneiform mit unmittelbarem zerfall und wirkstofffreisetzung |
| WO2005097789A1 (de) | 2004-04-01 | 2005-10-20 | Bayer Healthcare Ag | Neue kristalline form von 8-cyan-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure |
| WO2005097064A2 (en) | 2004-04-12 | 2005-10-20 | Pfizer Products Inc. | Taste-masked drugs in rupturing multiparticulates |
Non-Patent Citations (62)
| Title |
|---|
| Adeyeye C. M., Price J. C., Development and Evaluation of Sustained-Release Ibuprofen-Wax Microspheres .1. Effect of Formulation Variables on Physical Characteristics, Pharmaceutical Research, 1991; (8): 1377-1383 |
| Adeyeye C. M., Price J. C., Development and Evaluation of Sustained-Release Ibuprofen-Wax Microspheres .2. In-Vitro Dissolution, Pharmaceutical Research, 1994; (11): 575-579 |
| Adeyeye und Price, 1991 |
| Adeyeye und Price, 1994 |
| Al-Omran et al., 2002 |
| Al-Omran M. F., Al-Suwayeh S. A., El-Helw A. M., Saleh S. I., Taste masking of diclofenac sodium using microencapsulation, Journal of Microencapsulation, 2002; (19): 45-52 |
| Barra et al., 1999 |
| Barra J., Lescure F., Doelker E., Taste masking as a consequence of the organisation of powder mixes, Pharmaceutica Acta Helvetiae, 1999; (74): 37-42 |
| Barthelemy et al., 1999 |
| Barthelemy P., Laforet J. P., Farah N., Joachim J., Compritol (R) 888 ATO: an innovative hot-melt coating agent for prolonged-release drug formulations, European Journal of Pharmaceutics and Biopharmaceutics, 1999; <?page 12?>(47): 87-90 |
| Bienz M., Taste masking strategies for drug dosage forms, Manufacturing Chemist, 1996; (67): 17-20 |
| Bienz, 1996 |
| Breitkreutz et al., 2003 |
| Breitkreutz J., El-Saleh F., Kiera C., Kleinebudde P., Wiedey W., Pediatric drug formulations of sodium benzoate: II. Coated granules with a lipophilic binder, European Journal of Pharmaceutics and Biopharmaceutics, 2003; (56): 255-260 |
| Cerea et al., 2004 |
| Cerea M., Zheng W. J., Young C. R., McGinity J. W., A novel powder coating process for attaining taste masking and moisture protective films applied to tablets, International Journal of Pharmaceutics, 2004; (279): 127-139 |
| Chun M. K., Choi H. K., Preparation and characterization of enrofloxacin/carbopol complex in aqueous solution, Archives of Pharmacal Research, 2004; (27): 670-675 |
| Chun und Choi, 2004 |
| Katsuragi et al., 1997 |
| Katsuragi Y., Mitsui Y., Umeda T., Otsuji K., Yamasawa S., Kurihara K., Basic studies for the practical use of bitterness inhibitors: Selective inhibition of bitterness by phospholipids, Pharmaceutical Research, 1997; (14): 720-724 |
| Kim E. -H., Choi H. K., Preparation of various solid-lipid beads for Drug Delivery of Enrofloxacin, Drug Delivery, 2004; (11): 365-370 |
| Kim und Choi, 2004 |
| Li et al., 2002 |
| Li et al., 2006 |
| Li F. -Q., Hu J. -H., Deng J. -X., Su H., Xu S., Liu J. -Y., In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets, International Journal of Pharmaceutics, 2006; (324): 152-157 |
| Li S. P., Martellucci S. A., Bruce R. D., Kinyon A. C., Hay M. B., Higgins J. D., Evaluation of the film-coating properties of a hydroxyethyl cellulose/hydroxypropyl methylcellulose polymer system, Drug Development and Industrial Pharmacy, 2002; (28): 389-401 |
| Lovrecich et al., 1996 |
| Lovrecich M., Nobile F., Rubessa F., Zingone G., Effect of ageing on the release of indomethacin from solid dispersions with Eudragits, International Journal of Pharmaceutics, 1996; (131): 247-255 |
| Lu et al., 1991 |
| Lu M. Y. F., Borodkin S., Woodward L., Li P., Diesner C., Hernandez L., Vadnere M., A Polymer Carrier System for Taste Masking of Macrolide Antibiotics, Pharmaceutical Research, 1991; (8): 706-12 |
| Mirghani A., Idkaidek N. M., Salem M. S., Najib N. M., Formulation and release behavior of diclofenac sodium in Compritol 888 matrix beads encapsulated in alginate, Drug Development and Industrial Pharmacy, 2000; (26): 791-795 |
| Mirghani et al., 2000 |
| Ohta M., Buckton G., The use of inverse gas chromatography to assess the acid-base contributions to surface energies of cefditoren pivoxil and methacrylate copolymers and possible links to instability, International Journal of Pharmaceutics, 2004; (272): 121-128 |
| Ohta und Buckton, 2004 |
| Pearnchob et al., 2003a |
| Pearnchob et al., 2003b |
| Pearnchob N., Dashevsky A., Siepmann J., Bodmeier R., Shellac used as coating material for solid pharmaceutical dosage forms: understanding the effects of formulation and processing variables, Stp Pharma Sciences, 2003a; (13): 387-396 |
| Pearnchob N., Siepmann J., Bodmeier R., Pharmaceutical applications of shellac: Moisture-protective and taste-masking coatings and extended-release matrix tablets, Drug Development and Industrial Pharmacy, 2003b; (29): 925-938 |
| Petereit H. U., Weisbrod W., Formulation and process considerations affecting the stability of solid dosage forms formulated with methacrylate copolymers, European Journal of Pharmaceutics and Biopharmaceutics, 1999; (47): 15-25 |
| Petereit und Weisbrod, 1999 |
| Prompruk et al., 2005 |
| Prompruk K., Govender T., Zhang S., Xiong C. D., Stolnik S., Synthesis of a novel PEG-blockpoly(aspartic acid-stat-phenylalanine) copolymer shows potential for formation of a micellar drug carrier, International Journal of Pharmaceutics, 2005; (297): 242-253 |
| Reitz C, Kleinebudde P., Solid lipid extrudion of sustained release dosage forms. European Journal Of Pharmaceutics and Biopharmaceutics, 2007 doi:10.1016/j.ejpb.2007.03.008 |
| Reitz und Kleinebudde, 2007 |
| Roy G., Taste masking in oral pharmaceuticals, Pharmaceutical technology Europe, 1994; (18): 84-99 |
| Roy, 1994 |
| Schubert M. A. S. B. C., Thermal analysis of the drystallization and melting behavior of lipid matrices and lipid nanoparticles containing high amounts of lecithin, International Journal of Pharmaceutics, 2005; (298): 242-254 |
| Schubert, 2005 |
| Shirai et al., 1993 |
| Shirai Y., Sogo K., Yamamoto K., Kojima K., Fujioka H., Makita H., Nakamura Y., A Novel Fine Granule System for Masking Bitter Taste, Biological & Pharmaceutical Bulletin, 1993; (16): 172-177 |
| Sohi et al., 2004 |
| Sohi H., Sultana Y., Khar R. K., Taste masking technologies in oral pharmaceuticals: Recent developments and approaches, Drug Development and Industrial Pharmacy, 2004; (30): 429-448 |
| Suzuki et al., 2003 |
| Suzuki et al., 2004 |
| Suzuki H., Onishi H., Hisamatsu S., Masuda K., Takahashi Y., Iwata M., Machida Y., Acetaminophen-containing chewable tablets with suppressed bitterness and improved oral feeling, International Journal of Pharmaceutics, 2004; (278): 51-61 |
| Suzuki H., Onishi H., Takahashi Y., Iwata M., Machida Y., Development of oral acetaminophen chewable tablets with inhibited bitter taste, International Journal of Pharmaceutics, 2003; (251): 123-132 |
| Takagi et al., 2001 |
| Takagi S., Toko K., Wada K., Ohki T., Quantification of suppression of bitterness using an electronic tongue, Journal of Pharmaceutical Sciences, 2001; (90): 2042-2048 |
| Zhou et al., 1996 |
| Zhou et al., 1998 |
| Zhou F., Vervaet C., Remon J. P., Matrix pellets based on the combination of waxes, starches and maltodext<?page 13?>rins, International Journal of Pharmaceutics, 1996; (133): 155-160 |
| Zhou F., Vervaet C., Schelkens M., Lefebvre R., Remon J. P., Bioavailability of ibuprofen from matrix pellets based on the combination of waxes and starch derivatives, International Journal of Pharmaceutics, 1998; (168): 79-84 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2170272B1 (de) | Extrudate mit verbesserter geschmacksmaskierung | |
| DE69232837T3 (de) | Oxycodonhaltiges Arzneimittel mit verzögerter Wirkstoffabgabe | |
| DE69535445T2 (de) | Schmelzextrudierte oral verabreichbare Opioidformulierungen | |
| EP1818047A2 (de) | Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe | |
| WO2012010669A2 (de) | Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer | |
| DE102009015702A1 (de) | Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung | |
| EP1682144B1 (de) | Geschmacksstoffhaltige arzneimittelformulierungen mit verbesserten pharmazeutischen eigenschaften | |
| WO2003101422A2 (de) | Pharmazeutiche zubereitungen zur oralen anwendung enthaltend wirkstoffbeladene ionentauscherharze sowie strukturviskose gelbildner als verdicker | |
| EP2373287B1 (de) | Extrudate mit nadelförmigen wirkstoffen | |
| WO1994026267A1 (de) | Zubereitungen in form fester lösungen | |
| DE102011053068A1 (de) | Darreichungsform mit stabilisierten Wirkstoffpartikeln | |
| EP1663160A2 (de) | Schmelzformulierte, multipartikuläre orale darreichungsform enthaltend clavulansäure | |
| DE102012221900A1 (de) | Feste Lösungen von Coffein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: BAYER ANIMAL HEALTH GMBH, 51373 LEVERKUSEN, DE |
|
| R081 | Change of applicant/patentee |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE Free format text: FORMER OWNER: BAYER ANIMAL HEALTH GMBH, 51373 LEVERKUSEN, DE Effective date: 20121119 |
|
| R120 | Application withdrawn or ip right abandoned |
Effective date: 20140606 |